TITLE

Azathioprine treatment in multiple sclerosis; pretreatment assessment of metaboliser status

AUTHOR(S)
THOMAS, F. J.; HUGHES, T. A. T.; ANSTEY, A.
PUB. DATE
June 2001
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jun2001, p815
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66877951

 

Related Articles

  • Azathioprine.  // Reactions Weekly;4/8/2006, Issue 1096, p6 

    Presents a two cases of myelosuppression in patients during treatment with azathioprine for multiple sclerosis. Medical history of the patients; Symptoms experienced by the patients.

  • Azathioprine in Multiple Sclerosis. Invernizzi, Paolo; Benedetti, Maria Donata; Poli, Sarah; Monaco, Salvatore // Mini Reviews in Medicinal Chemistry;Aug2008, Vol. 8 Issue 9, p919 

    Azathioprine is an immunosuppressive and steroid-sparing purine analogue, used in the treatment of several autoimmune diseases. In multiple sclerosis, available evidence suggests that oral azathioprine reduces relapse rates, provides a slight benefit on disability, and reduces new inflammatory...

  • Multiple sclerosis: therapeutic pessimism. Webb, H.E. // BMJ: British Medical Journal (International Edition);5/16/92, Vol. 304 Issue 6837, p1260 

    Examines the treatment of multiple sclerosis. Efficacy of cyclophosphamide and azathioprine; Impact of polyunsaturated fatty acids on patients with the disease; Correlations between fatty acids and myelin.

  • Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Bojar, M.; Zajac, M.; Meluz�nova, E.; Hou�vickov�, E.; Libertinov�, J.; Li�kov�, P.; Mat'o�ka, V.; Nyc, O.; Min�rikov�, M. // Multiple Sclerosis (13524585);12/01/2010, Vol. 16 Issue 12, p1529 

    A letter to the editor is presented in response to the article "Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis," by M. Ravnborg and colleagues.

  • Response to letter from Dr Martin Bojar and colleagues regarding the article �Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple ... Ravnborg, Mads; S�rensen, Per Soelberg // Multiple Sclerosis (13524585);12/01/2010, Vol. 16 Issue 12, p1531 

    A response by Mads Ravnborg to a letter to the editor on his article "Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis" is presented.

  • Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases. Constantinescu, C.S.; Whiteley, A.; Blumhardt, L.D. // Multiple Sclerosis (13524585);Oct2000, Vol. 6 Issue 5, p362 

    Azathioprine is an immunosuppressive drug widely used in the treatment of chronic inflammatory diseases, including Multiple Sclerosis (MS). We report two patients who developed the first manifestations of clinically definite multiple sclerosis while on long term (3.5 and 10 years, respectively)...

  • Old Drugs-Current Perspectives. Coulthard, S. A.; Hogarth, L. A. // Current Pharmacogenomics;Jun2004, Vol. 2 Issue 2, p163 

    The thiopurine drugs, 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used in the treatment of acute leukaemias. A derivative of 6-MP, azathioprine, and 6-MP itself are used as immunosuppressants, in the treatment of inflammatory bowel disease, autoimmune conditions and following...

  • Azathioprine for multiple sclerosis. I Casetta // Journal of Neurology, Neurosurgery & Psychiatry;Feb2009, Vol. 80 Issue 2, p131 

    BACKGROUND: Azathioprine (AZA) is an immunosuppressive drug widely prescribed for the treatment of multiple sclerosis (MS) until the first half of the 1990s. It could be an alternative to interferon β because it is less expensive. Concerns about its safety, mainly a possible increased risk of...

  • Azathioprine Therapy in Multiple Sclerosis: Phosphoribosylated Metabolites and Thiopurine Methyltransferase Activity. Albrecht, Peter; Tafazzoli-Lari, Julia; Iven, Heiko; Moser, Andreas // Open Neuroscience Journal;2014, Vol. 8, p9 

    Objective: In this prospective study, we examined the association between azathioprine dose, levels of its phosphoribosylated metabolites, and the activity of thiopurine methyltransferase in patients with multiple sclerosis (MS). Materials/Methods: Clinical data and blood samples were collected...

  • Treatment Optimization in Multiple Sclerosis. Freedman, Mark S.; Patry, David G.; Grand'Maison, François; Myles, Mary Lou; Paty, Donald W.; Selchen, Daniel H. // Canadian Journal of Neurological Sciences;May2004, Vol. 31 Issue 2, p157 

    Discusses improvements in the treatment of multiple sclerosis. Mechanics of disease-modifying therapies; Assessment of status of the patient; Analog models to assess effectiveness of therapeutic strategies; Recommendations; Magnetic resonance imaging; Other possible factors affecting treatment...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics